Oramed Pharmaceuticals Inc.

Regulatory Filings • Apr 14, 2019

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person RAKIN KEVIN						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									X Director	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Officer (give title		10% Owner
(Last) (First) (Middle) 36 CHURCH LANE					3. Date of Earliest Transaction (Month/Day/Year) 04/10/2019										below)			below)	Other (specify
(Street) WESTPORT CT 06880 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. and 5) 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned		(D) or	6. Ownership Form: Direct Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	V	Amount	(A) or (D)		Price	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of	8. Price Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code		V (A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$4.17	04/10/2019			A		10,000		12/31/2019 04/10/2029			Common Stock	10,000		\$0	10,000		D

Explanation of Responses:

/s/ Kevin Rakin 04/12/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.